An Open-Label, Phase 1 Study to Characterize the Effects of a Strong Cytochrome P450 3A4 Inducer on the Pharmacokinetics of Bomedemstat in Healthy Adult Participants
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Bomedemstat (Primary) ; Carbamazepine
- Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 27 Nov 2024 Planned End Date changed from 25 Nov 2024 to 16 Feb 2025.
- 27 Nov 2024 Planned primary completion date changed from 25 Nov 2024 to 3 Feb 2025.
- 02 Oct 2024 Status changed from not yet recruiting to recruiting.